Additionally, the HDAC inhibitors Entinostat and Romidepsin have been shown to synergize with Doxorubicin in vitro, and inhibit tumor growth when combined with an embryonic ectoderm development (EED, a protein which is part of the PRC2 complex) inhibitor in vivo. The gene discussed is EED; the disease is neoplasm.